TLX-101 is a small molecule commercialized by Telix Pharmaceuticals, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM). According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of TLX-101’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for TLX-101 is expected to reach an annual total of $32 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ACD-101 (131I-ACD-101) is under development for the treatment of glioblastoma multiforme, recurrent glioblastoma multiforme. The drug is administered intravenously. ACD-101 is a phenylalanine derivative that contains an iodine atom. It is a synthetic amino acid. ACD-101 is a radiation sensitizer which increases tumor killing in connection with standard external field radiation therapy (XRT), or intracellular endo-radiation therapy (ERT), using 131I-ACD-101. It acts by targeting DNA and LAT-1 (L-type amino acid transporter).
Telix Pharmaceuticals Overview
Telix Pharmaceuticals (Telix) is a biopharmaceutical company that develops and commercializes radiopharmaceuticals to detect and treat cancer. It offers Illuccix, an imaging agent targeting men with prostate cancer. The company is investigating TLX250-CDx (companion diagnostic) an imaging agent to diagnose renal cancer using positron emission tomography (PET); and TLX250, a radiopharmaceutical therapy against renal cancer. Telix is also evaluating TLX591, an antibody-based therapeutic radiopharmaceutical to treat prostate cancer; TLX101 drug for the treatment of glioblastoma (GBM); and TLX66-CDx and TLX66 programs for bone marrow conditioning. It utilizes molecularly-targeted radiation (MTR) technology, where a radionuclide is attached to a targeting small molecule or antibody that binds to tumor cells and destroys them. The company operates in the US, Japan, and Belgium. Telix is headquartered in Melbourne, Victoria, Australia.
The company reported revenues of (Australian Dollars) AUD7.6 million for the fiscal year ended December 2021 (FY2021), an increase of 45.7% over FY2020. The operating loss of the company was AUD75.3 million in FY2021, compared to an operating loss of AUD46.8 million in FY2020. The net loss of the company was AUD80.5 million in FY2021, compared to a net loss of AUD44.9 million in FY2020.
For a complete picture of TLX-101’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.